Cancer Immunotherapy in Children Could See Improvements with Earlier Lineage T-Cells

Cancer Immunotherapy in Children Could See Improvements with Earlier Lineage T-Cells
0
(0)

Pediatric oncologists from the Children’s Hospital of Philadelphia (CHOP) have investigated techniques to improve and expand a novel personalized cell therapy to treat children with acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL).

Scientists believe that the outcome of cancer patients may improve upon the selection of specific T-cell subtypes to target these types of cancers. The research paper, “Early memory phenotypes drive T-cell proliferation in patients with pediatric malignancies,” was published in Science Translational Medicine.

Adoptive T-cell transfer is an immunotherapy strategy in which T-cells extracted from a patient are engineered to recognize and destroy cancer cells. After T-cells are extracted from the blood, researchers genetically introduce potent receptors into the cells to target cancer cells. The T-cells are then re-introduced into the patient’s circulation system and, ideally, travel to the tumor site and kill malignant cells.

This type of engineered T-cell therapy has shown promising results in B-cell malignancies, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL), where cancer is treatment-resistant or relapsing. Despite such efficacy, many patients are unable to receive T-cell therapy because their cells fail to expand in vitro (in the lab), an essential part of the process and also a predictor of cell viability in vivo.

To understand the biological and functional differences underlying this process, the researchers followed 38 ALL and 12 NHL child and adolescent patients enrolled in a B-cell cancer clinical trial at the Children’s Hospital of Philadelphia.

The scientists studied immune system makers, T-cell population expansion potential and memory phenotype, characterizing the T-cells once a month for six months following diagnosis. Results revealed that T-cells expanded from earlier lineages — such as naïve T-cells and stem-central memory T-cells — had better expansion profiles in the laboratory and were also the most effective for immunotherapy.

In addition, enrichment of cell culture with interleukin-7 and interleukin-15 rescued T-cell expansion capability and enriched stem-central memory cells in samples from both ALL and NHL patients. Importantly, ALL patients had different mixtures of T-cell subtypes when compared to NHL patients, along with higher numbers of early lineage T-cells, which possess a bigger expansion potential.

“In newly diagnosed patients, it may be preferable to collect their T-cells much earlier than currently done, before chemotherapy, or between chemotherapy cycles, instead of after a patient relapses. We could keep the patient’s early-lineage T-cells in reserve in case the patient needs them later,” senior author David M. Barrett, MD, said in a press release

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • FDA fast track
  • cancer trial of probody
  • Lurbinectedin
  • Opdivo -Yervoy combo

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?